inmune
bio
report
third
quarter
financial
results
provide
corporate
update
thursday
november
management
host
conference
call
pm
et
day
la
jolla
calif
globe
newswire
inmune
bio
nasdaq
inmb
company
inmune
immunology
company
focused
developing
treatments
harness
patient
innate
immune
system
fight
disease
today
announced
host
conference
call
thursday
november
pm
eastern
time
discuss
results
third
quarter
ended
september
provide
corporate
update
conference
call
information
participate
event
dial
approximately
minutes
beginning
call
please
ask
inmune
bio
third
quarter
conference
call
reaching
operator
date
november
time
pm
eastern
time
participant
participant
international
transcript
follow
approximately
hours
scheduled
call
replay
also
available
november
dialing
international
entering
pin
inmune
bio
inmune
bio
publicly
traded
nasdaq
inmb
biotechnology
company
focused
developing
treatments
target
innate
immune
system
fight
disease
inmune
bio
two
product
platforms
product
platform
utilizes
technology
selectively
neutralize
soluble
tnf
key
driver
innate
immune
dysfunction
mechanistic
target
many
diseases
currently
clinical
trials
determine
help
treat
complications
cancer
alzheimer
treatment
resistant
depression
nash
natural
killer
cell
priming
platform
includes
aimed
priming
patient
nk
cells
eliminate
minimal
residual
disease
patients
cancer
inmune
bio
product
platforms
utilize
precision
medicine
approach
treatment
wide
variety
hematologic
malignancies
solid
tumors
chronic
inflammation
learn
please
visit
forward
looking
statements
company
clinical
trials
early
stages
assurance
specific
outcome
achieved
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
contained
herein
based
current
expectations
subject
number
risks
uncertainties
actual
results
timing
certain
events
circumstances
may
differ
materially
described
statements
result
risks
uncertainties
livnate
inkmune
still
clinical
trials
preparing
start
clinical
trials
approved
assurance
approved
specific
results
achieved
two
platforms
beginning
clinical
trials
assurance
success
trials
factors
could
cause
actual
future
results
differ
materially
current
expectations
include
limited
risks
uncertainties
relating
company
ability
produce
drug
clinical
trials
availability
substantial
additional
funding
company
continue
operations
conduct
research
development
clinical
studies
future
product
commercialization
company
business
research
product
development
regulatory
approval
marketing
distribution
plans
strategies
factors
identified
described
detail
company
filings
securities
exchange
commission
including
company
annual
report
form
company
quarterly
reports
form
company
current
reports
form
company
assumes
obligation
update
statements
order
reflect
event
circumstance
may
arise
date
release
inmune
bio
contact
david
moss
cfo
dmoss
